Core Viewpoint - HaiXi New Drug (02637) announced its investment strategy to utilize idle funds effectively by subscribing to structured notes and a fund, aiming to enhance capital returns while ensuring liquidity and meeting operational needs [1] Group 1: Investment Details - The company plans to invest HKD 200 million in structured notes issued by Essence Global Investment Limited under its USD 1 billion secured structured note program [1] - Additionally, the company will subscribe up to HKD 200 million in China Rock Fund SPC, collectively referred to as the subscription matters [1] Group 2: Financial Strategy - The investment aligns with the company's core objective of improving capital returns while ensuring the safety and liquidity of funds [1] - The strategy also aims to meet the group's daily operational and dividend payment funding requirements [1]
海西新药认购金融产品